Sunshine Biopharma (SBFM) Change in Accured Expenses (2012 - 2026)

Sunshine Biopharma has reported Change in Accured Expenses for 15 years, with the latest figure at -$455836.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 6.21% year-over-year to -$455836.0; the trailing twelve-month figure through Mar 2026 stood at -$159783.0 (down 107.25% YoY), and the FY2025 full-year result was -$189956.0, down 104.77% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$455836.0, up from -$565040.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.4 million in Q4 2022, with the low at -$1.0 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged $313703.8 across 5 years, with a median of -$73661.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 8927.5% — and 2023, when it slumped 1035.97%.
• Sunshine Biopharma's Change in Accured Expenses stood at $3.4 million in 2022, then slumped by 122.78% to -$776161.0 in 2023, then surged by 326.07% to $1.8 million in 2024, then slumped by 132.2% to -$565040.0 in 2025, then grew by 19.33% to -$455836.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$455836.0 (Q1 2026), -$565040.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.